Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences (RNA) Non-Current Debt: 2019

  • Avidity Biosciences' Non-Current Debt was N/A to $1.8 million in Q4 2019 from the same period last year, while for Dec 2019 it was $1.8 million, marking a year-over-year change of. This contributed to the annual value of $1.8 million for FY2019, which is N/A change from last year.
  • As of Q4 2019, Avidity Biosciences' Non-Current Debt stood at $1.8 million.
  • Over the past 5 years, Avidity Biosciences' Non-Current Debt peaked at $1.8 million during Q4 2019, and registered a low of $1.8 million during Q4 2019.
  • Moreover, its 1-year median value for Non-Current Debt was $1.8 million (2019), whereas its average is $1.8 million.